Please assess the completion status of the following clinical trial:

Trial Title: Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18~2. The patient has unrespectable or metastatic melanoma with progressive, persistent or recurrent disease on or following treatment with standard of care agents~3. Patients belonging to one of the following patient groups will be enrolled:~   Cohort A: Anti PD-1/PD-L1 naïve patients (30 patients). The patient is a candidate for Nivolumab monotherapy. Prior anti-PD-1/anti-PD-L1 antibody treatment is not allowed.~   OR Cohort B: Extension cohort (10 patients). Progressive disease ON anti-PD-1 monotherapy.Subjects should not have experienced serious and/or life-threatening toxicity to antibody therapy.~   OR Cohort C: Extension cohort (10 patients). Progressive disease during follow up OFF anti-PD-1 after clinical benefit (SD/PR/CR) on anti-PD-1 therapy. Subjects should not have discontinued antibody therapy due to serious and/or lifethreatening toxicity~4. At least one measurable parameter according to RECIST 1.1.~5. The patient has an ECOG performance status of 0 or 1~6. The patient is a female of childbearing potential with negative pregnancy test~7. For women: Agreement to use contraceptive methods with a failure rate of \< 1 % per year during the treatment period and for at least 120 days after the treatment~8. For men: Agreement to use contraceptive measures and agreement to refrain from donating sperm~9. The patient has met the following hematological and biochemical criteria:~   1. AST and ALT ≤2,5 X ULN or ≤5 X ULN with liver metastases~  2. Serum total bilirubin ≤1,5 X ULN or direct bilirubin ≤ ULN for patient with total bilirubin level \> 1,5 ULN~  3. Serum creatinine ≤1,5 X ULN~  4. ANC (Absolute Neutrophil Count) ≥1,000/mcL~  5. Platelets ≥ 75,000 /mcL~  6. Hemoglobin ≥ 9 g/dL eller ≥ 5.6 mmol/L~10. Signed declaration of content after oral and written information about the protocol.~Exclusion Criteria:~1. The patient has not recovered to grade 0-1 from adverse events due to prior chemotherapy, radioactive or biological cancer therapy~2. The patient has not recovered from surgery or is less than 4 weeks from major surgery~3. The patient has a history of life-threatening or severe immune related adverse events on treatment with another immunotherapy and is considered to be at risk of not recovering~4. The patient is expected to require any other form of systemic antineoplastic therapy while receiving the treatment~5. The patient has a history of severe clinical autoimmune disease~6. The patient has a history of pneumonitis, organ transplant, human immunodeficiency virus positive, active hepatitis B or hepatitis C~7. The patient requires systemic steroids for management of immune-related adverse events experienced on another immunotherapy~8. The patient has active CNS metastases and/or carcinomatous meningitis. However, patients with subclinical brain metastases \< 1 cm can be included (maximum of 4 metastases \< 1 cm). (Patients with previously treated brain metastases may participate provided they are clinically stable. Patients with untreated brain metastasis will be excluded)~9. The patient has any condition that will interfere with patient compliance or safety (including but not limited to psychiatric or substance abuse disorders)~10. The patient is pregnant or breastfeeding~11. The patient is unable to voluntarily agree to participate by signed informed consent or assent~12. The patient has an active infection requiring systemic therapy~13. The patient has received a live virus vaccine within 30 days of planned start of therapy~14. Known side effects to Montanide ISA-51~15. Significant medical disorder according to investigator; e.g. severe asthma or chronic obstructive lung disease, dysregulated heart disease or dysregulated diabetes mellitus~16. Concurrent treatment with other experimental drugs~17. Any active autoimmune diseases e.g. autoimmune neutropenia, thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, autoimmune glomerulonephritis, autoimmune adrenal deficiency, autoimmune thyroiditis etc.~18. Severe allergy or anaphylactic reactions earlier in life

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient group (Type: EXPERIMENTAL): All patients receive the same treatment. Patients included in the protocol are treated with Nivolumab according to usual guidelines, implying outpatient IV infusions of 3 mg/kg biweekly until progression.~The vaccine is administered on the same day as the administration start of Nivolumab. The vaccination is given biweekly for a total of 6 times, then every fourth week up to week 47, whereupon no additional vaccines will be given. In total, 15 vaccines will be administered. A vaccine consist of 100 μg IDO long peptide, 100 μg PD-L1 long1 peptide and 500 microliters Montanide as adjuvant.~Patients who complete all vaccines will continue Nivolumab treatment after standard guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete